Financials in USD. Standardized financial statements.
A compact view of how Neuphoria Therapeutics Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $15.65M | $0 | $0 | $383,156 | $0 | $32,062 | $2.68M | $2.76M | $4.13M | $5.21M |
| Revenue Growth? | 0.0% | 0.0% | -100.0% | 0.0% | -100.0% | -98.8% | -2.9% | -33.3% | -20.8% | 0.0% |
| Cost of Revenue? | $0 | $662,991 | $671,476 | $16.00M | $0 | $0 | $12.13M | $25.25M | $24.22M | $24.77M |
| Gross Profit? | $15.65M | -$662,991 | -$671,476 | $383,156 | $0 | $32,062 | $2.68M | $2.76M | $4.13M | $5.21M |
| Gross Margin? | +100.0% | 0.0% | 0.0% | +100.0% | 0.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $16.78M | $26.79M | $33.09M | $31.40M | $8.96M | $6.23M | $13.43M | $24.04M | $14.93M | $26.89M |
| Operating Income? | -$1.13M | -$26.79M | -$33.09M | -$31.02M | -$8.96M | -$6.19M | -$10.76M | -$21.28M | -$10.80M | -$21.68M |
| EBITDA? | -$121,896 | -$25.65M | -$31.45M | -$30.25M | -$4.51M | -$1.23M | -$11.21M | -$22.38M | -$3.75M | -$14.16M |
| Income Before Tax | -$837,998 | -$23.32M | -$32.39M | -$31.90M | -$6.68M | -$4.14M | -$6.94M | -$19.28M | -$4.79M | -$12.94M |
| Income Tax Expense | -$468,366 | -$130,726 | -$209,471 | -$278,767 | -$140,820 | -$142,654 | -$165,795 | -$852,960 | $401,573 | -$534,218 |
| Net Income? | -$369,632 | -$23.19M | -$32.18M | -$31.62M | -$6.53M | -$4.89M | -$6.77M | -$18.43M | -$5.19M | -$12.40M |
| EPS? | $-0.23 | $-0.10 | $-0.18 | $-0.20 | $-0.10 | $-0.11 | $-0.16 | $-0.46 | $-0.13 | $-0.33 |
| Diluted EPS? | $-0.23 | $-0.10 | $-0.18 | $-0.20 | $-0.10 | $-0.11 | $-0.16 | $-0.46 | $-0.13 | $-0.33 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality